Developmental history of neurorestoratology

Huang, Hongyun; Chen, Lin; Sanberg, Paul R.

doi:10.2147/jn.s74138

Cited by 3 publications

(6 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The American Spinal Injury Association (ASIA) neurological score is the most widely used quantitative neurological assessment. Quality of life is evaluated using the International Association of Neurorestoratology SCI Functional Rating Scale [14,15].…”

Section: Acute and Subacute Stages Of Sci 21 Assessmentmentioning

confidence: 99%

“…In addition to treatment of the primary injury, secondary SCI requires attention [9,[14][15][16]. The main purpose of SCI treatment is to reduce secondary injury in the acute and subacute stages.…”

Section: Treatmentsmentioning

confidence: 99%

“…Other drugs, including erythropoietin, riluzole, minocycline, sex hormone, neurotrophic factor, sodium aescinate, axonal growth promoting agent, granulocyte colony stimulating factor, magnesium agent, and fibroblast growth factor [2] are in clinical trials or have been in clinical use, but high-level evidence to support their routine use is lacking [15,45,[51][52][53]. Although intravenous vasopressor agents such as norepinephrine can improve local spinal cord perfusion pressure and hemodynamics after SCI [54][55][56], their effect on neurological recovery is uncertain.…”

Section: Drug Therapymentioning

confidence: 99%

“…In view of the rapid developments in neurorestorative therapy for SCI, the Chinese Association of Neurorestoratology (Preparatory) and China Committee of International Association of Neurorestoratology revised and updated the Clinical Therapeutic Guidelines for Neurorestoration in SCI in 2016 [14]. SCI can be divided into four stages according to time: acute (< 48 h), subacute (48 h -14 d), intermediate (14 d-6 months), and chronic (> 6 months) [15]. The guidelines presented here are based on evidence published before 31 December, 2020.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Clinical guidelines for neurorestorative therapies in spinal cord injury (2021 China version)

Guo¹,

Feng²,

Sun³

et al. 2021

Journal of Neurorestoratology

Self Cite

View full text Add to dashboard Cite

Treatment of spinal cord injury (SCI) remains challenging. Considering the rapid developments in neurorestorative therapies for SCI, we have revised and updated the Clinical Therapeutic Guidelines for Neurorestoration in Spinal Cord Injury (2016 Chinese version) of the Chinese Association of Neurorestoratology (Preparatory) and China Committee of International Association of Neurorestoratology. Treatment of SCI is a systematic multimodal process that aims to improve survival and restore neurological function. These guidelines cover real-world comprehensive neurorestorative management of acute, subacute, and chronic SCI and include assessment and diagnosis, pre-hospital first aid, treatment, rehabilitation, and complication management.

show abstract

Section: Acute and Subacute Stages Of Sci 21 Assessmentmentioning

confidence: 99%

Section: Treatmentsmentioning

confidence: 99%

Section: Drug Therapymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical guidelines for neurorestorative therapies in spinal cord injury (2021 China version)

Guo¹,

Feng²,

Sun³

et al. 2021

Journal of Neurorestoratology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Findings obtained about clinical trials for SCI treatment demonstrated that the efficacy of MSCs in human studies is not beneficial like in preclinical studies [45]. For these reasons protocol standardization of basic and preclinical studies using MSCs should emphasize to translate to the clinical setting.…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal Stem Cell Therapies for Paraplegia: Preclinical and Clinical Studies

Kazemnejad¹,

Mousavizadeh²,

Joghataei³

2021

Paraplegia

View full text Add to dashboard Cite

Paraplegia is the damage or loss of function in motor and/or sensory abilities. This insult can be observed in the thoracic, lumbar, or sacral parts of spinal column. Besides, paraplegia may be occurring because of any injuries or diseases of the lower segments or peripheral nerves or by cerebral palsy (CP). This damage can be seen as a result of a tumor or blood clot on the spinal cord. By now, there is not any curative treatment for paraplegia. Using mesenchymal stem cells (MSCs) in the treatment of spinal cord injury is a promising tested strategy because of their simplicity of isolation/preservation and their properties. Several preclinical studies in this field can be found; however, MSCs showed weak and conflicting outcomes in trials. In this chapter book, we will discuss about the therapeutic role of these cells in the treatment of paraplegia, with emphasis on their characterization, relevance, boundaries, and prospect views.

show abstract